BeiGene to Host Investor Research and Development Day in Person and via Webcast on July 18, 2023
07 July 2023 - 9:00PM
Business Wire
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global
biotechnology company, today announced that the Company will host
an investor Research and Development Day in New York City and via
webcast on July 18, 2023. John V. Oyler, BeiGene's Co-Founder,
Chairman and CEO, along with the Company's leadership team, will
provide an update on BeiGene’s deep and broad global innovation
pipeline and platforms, and share insights on the Company's vision,
differentiated capabilities, and value creation drivers.
Live webcast of this event can be accessed from the investors
section of BeiGene’s website at http://ir.beigene.com ,
http://hkexir.beigene.com or https://sseir.beigene.com. Archived
replays will be available for 90 days following the event.
About BeiGene
BeiGene is a global biotechnology company that is discovering
and developing innovative oncology treatments that are more
affordable and accessible to cancer patients worldwide. With a
broad portfolio, we are expediting development of our diverse
pipeline of novel therapeutics through our internal capabilities
and collaborations. We are committed to radically improving access
to medicines for far more patients who need them. Our growing
global team of more than 9,400 colleagues spans five continents,
with administrative offices in Basel; Beijing; and Cambridge, U.S.
To learn more about BeiGene, please visit www.beigene.com and
follow us on Twitter at @BeiGeneGlobal.
Forward-Looking Statements
This presentation may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and other federal securities laws, including statements regarding
BeiGene's plans, commitments, aspirations and goals related to
BeiGene’s medicines and drug candidates. Actual results may differ
materially from those indicated in the forward-looking statements
as a result of various important factors which are discussed in the
section entitled “Risk Factors” in BeiGene’s most recent quarterly
report on Form 10-Q filed with the U.S. Securities and Exchange
Commission (“SEC”) as well as discussions of potential risks,
uncertainties, and other important factors in BeiGene's subsequent
filings with the SEC. All information in this presentation is as of
the date presented, and BeiGene undertakes no duty to update such
information unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230707825257/en/
Investors: Liza Heapes +1 857-302-5663 ir@beigene.com
Media: Kyle Blankenship +1 667-351-5176
media@beigene.com
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Jun 2024 to Jul 2024
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Jul 2023 to Jul 2024